IA
CRVS icon

IFP Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

IFP Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24
Closed -$127 – 4605
2024
Q3 		$127 Hold
24
– – ﹤0.01% 3226
2024
Q2 		$44 Hold
24
– – ﹤0.01% 3184
2024
Q1 		$43 Hold
24
– – ﹤0.01% 3081
2023
Q4 		$42 Hold
24
– – ﹤0.01% 2992
2023
Q3 		$35 Hold
24
– – ﹤0.01% 3244
2023
Q2 		$55 Hold
24
– – ﹤0.01% 3383
2023
Q1 		$19 Hold
24
– – ﹤0.01% 3343
2022
Q4 		$1K Buy
+24
New +$21 ﹤0.01% 4307

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

IFP Advisors's CRVS Position: Q4 2024 in Review

IFP Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q4 2024, closing a stake of 24 shares — an estimated $127 sold.

IFP Advisors first reported a position in CRVS in Q4 2022 and held it in 8 quarters. The position peaked at $1K in Q4 2022. 85 funds tracked by Wall St. Rank hold CRVS as of Q4 2024.

  • IFP Advisors reported no remaining Corvus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • IFP Advisors sold 24 Corvus Pharmaceuticals shares in Q4 2024, an estimated $127.
  • IFP Advisors first reported a position in Corvus Pharmaceuticals in Q4 2022 and held it in 8 quarters.
  • IFP Advisors's Corvus Pharmaceuticals position peaked at $1K in Q4 2022.
  • 85 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2024.

Based on IFP Advisors's 13F filing for Q4 2024, filed 4 Feb 2025.